LRMR

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Larimar Therapeutics Inc

NASDAQ | LRMR

4.29

USD

$0.00

(

0.00%

)

At Close (As of Oct 21, 2025)

$372.32M

Market Cap

-

P/E Ratio

-1.63

EPS

$9.50

52 Week High

$1.61

52 Week Low

HEALTHCARE

Sector

LRMR Chart

Recent Chart
Price Action

LRMR Technicals

Tags:

LRMR Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$318K
Total Revenue $0
Cost Of Revenue $318K
Costof Goods And Services Sold $318K
Operating Income -$91M
Selling General And Administrative $18M
Research And Development $73M
Operating Expenses $91M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $318K
Income Before Tax -$81M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$81M
Comprehensive Income Net Of Tax -
Ebit -$81M
Ebitda -$80M
Net Income -$81M

Revenue & Profitability

Earnings Performance

LRMR Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $200M
Total Current Assets $195M
Cash And Cash Equivalents At Carrying Value $33M
Cash And Short Term Investments $33M
Inventory -
Current Net Receivables $1.1M
Total Non Current Assets $4.9M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $150M
Other Current Assets $11M
Other Non Current Assets -
Total Liabilities $28M
Total Current Liabilities $24M
Current Accounts Payable $2.4M
Deferred Revenue -
Current Debt -
Short Term Debt $1.1M
Total Non Current Liabilities $4.1M
Capital Lease Obligations $5.1M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $5.1M
Other Current Liabilities $21M
Other Non Current Liabilities -
Total Shareholder Equity $172M
Treasury Stock -
Retained Earnings -$269M
Common Stock $64K
Common Stock Shares Outstanding $61M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$71M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $318K
Capital Expenditures $515K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$85M
Cashflow From Financing $162M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$81M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$318K
Total Revenue $0
Cost Of Revenue $318K
Costof Goods And Services Sold $318K
Operating Income -$91M
Selling General And Administrative $18M
Research And Development $73M
Operating Expenses $91M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $318K
Income Before Tax -$81M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$81M
Comprehensive Income Net Of Tax -
Ebit -$81M
Ebitda -$80M
Net Income -$81M

LRMR News

LRMR Profile

Larimar Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company based in Bala Cynwyd, Pennsylvania, focused on developing innovative therapies for rare diseases characterized by significant unmet medical needs. Leveraging advanced technologies and deep scientific expertise, the company is committed to improving patient outcomes through its promising drug pipeline. With strategic partnerships and a clear vision for leadership in the rare disease sector, Larimar is well-positioned to deliver substantial value to its stakeholders while addressing critical health challenges.

BYND
+146.25%
$3.62
VHAI
0.00%
$0.00
YDKG
+27.99%
$0.05
YYAI
-19.18%
$0.08
F
+4.75%
$12.56
VSEE
+93.56%
$0.94
CGBS
-39.47%
$0.03
NERV
+140.97%
$6.41
RANI
+26.66%
$2.85
NVDA
-0.81%
$181.16
GDXD
+28.69%
$0.86
AIRE
+61.36%
$0.72
BURU
-14.84%
$0.28
BITF
-9.83%
$4.49
PLUG
-8.23%
$3.12
ADAP
-17.62%
$0.04
T
-0.19%
$26.05
RGTI
-7.64%
$40.00
HPE
+1.74%
$23.27
CAN
-4.87%
$1.95
DNN
-7.16%
$2.72
BTG
-9.12%
$5.18
INTC
+0.05%
$38.11
WBD
+10.97%
$20.32
BOF
+33.65%
$2.80
JOBY
-7.63%
$16.10
DVLT
+4.54%
$2.52
CLF
-17.24%
$13.39
AXDX
-61.36%
$0.03
IBIO
+24.30%
$1.11
GSIT
-16.26%
$10.86
RIG
+0.60%
$3.31
TLRY
-5.73%
$1.48
NVTS
-12.10%
$15.03
RXRX
-8.53%
$6.11
ETHD
-0.80%
$3.72
SOFI
+0.24%
$28.75
ABEV
-2.20%
$2.22
TSLA
-1.07%
$442.60
RF
+1.24%
$24.36
AMZN
+2.56%
$222.03
EOSE
+8.59%
$16.30
GRAB
-1.23%
$5.60
GOOGL
-2.37%
$250.46
AMD
-1.05%
$238.03
AAPL
+0.20%
$262.77
LAES
-5.86%
$6.10
QUBT
-7.40%
$16.00
ACHR
-4.75%
$11.41
IONZ
+1.48%
$4.11
GM
+14.86%
$66.62
SOUN
-4.35%
$18.23
RR
+1.25%
$5.63
BTBT
-8.29%
$3.87
VALE
-1.14%
$11.27
BBD
-2.36%
$3.30
IREN
-6.79%
$55.19
PFE
+0.64%
$24.85
QBTS
-6.42%
$32.19
GPUS
-7.57%
$0.36
DCGO
+24.16%
$1.49
MARA
-3.18%
$20.07
HAL
+11.58%
$25.24
RMBL
+60.50%
$3.21
CJET
-20.45%
$0.08
AAL
+1.47%
$12.35
DFLI
-3.96%
$1.21
ADD
-25.47%
$0.05
CLSK
-7.99%
$18.77
NOK
-2.27%
$5.58
NIO
-3.68%
$6.80
SRM
+53.27%
$10.30
CIFR
-9.21%
$18.07
BMNR
-3.62%
$51.85
AMC
+4.33%
$2.89
KO
+4.06%
$71.22
SNAP
+1.55%
$7.85
PBR
-1.11%
$11.56
ONDS
-7.46%
$7.19
SMR
-13.20%
$38.36
VZ
-1.22%
$40.29
HBAN
+0.63%
$15.94
HIMS
-3.89%
$49.36
CUTR
-10.19%
$0.09
WTO
+2.93%
$0.06
SMCI
-0.39%
$54.82
GGB
-1.17%
$3.37
EPWK
-8.71%
$0.07
WLGS
-5.57%
$0.04
PM
-3.83%
$152.00
RIVN
+0.91%
$13.20
GOOG
-2.20%
$251.34
PLTR
-0.04%
$181.51
BAC
-0.99%
$51.52
APLD
-9.35%
$32.54
RGTZ
+15.11%
$15.61
ETWO
0.00%
$3.30
BULL
-2.96%
$11.14
IONQ
-0.73%
$59.50
MSN
+59.31%
$0.76
BYND
+146.25%
$3.62
VHAI
0.00%
$0.00
YDKG
+27.99%
$0.05
YYAI
-19.18%
$0.08
F
+4.75%
$12.56
VSEE
+93.56%
$0.94
CGBS
-39.47%
$0.03
NERV
+140.97%
$6.41
RANI
+26.66%
$2.85
NVDA
-0.81%
$181.16
GDXD
+28.69%
$0.86
AIRE
+61.36%
$0.72
BURU
-14.84%
$0.28
BITF
-9.83%
$4.49
PLUG
-8.23%
$3.12
ADAP
-17.62%
$0.04
T
-0.19%
$26.05
RGTI
-7.64%
$40.00
HPE
+1.74%
$23.27
CAN
-4.87%
$1.95
DNN
-7.16%
$2.72
BTG
-9.12%
$5.18
INTC
+0.05%
$38.11
WBD
+10.97%
$20.32
BOF
+33.65%
$2.80
JOBY
-7.63%
$16.10
DVLT
+4.54%
$2.52
CLF
-17.24%
$13.39
AXDX
-61.36%
$0.03
IBIO
+24.30%
$1.11
GSIT
-16.26%
$10.86
RIG
+0.60%
$3.31
TLRY
-5.73%
$1.48
NVTS
-12.10%
$15.03
RXRX
-8.53%
$6.11
ETHD
-0.80%
$3.72
SOFI
+0.24%
$28.75
ABEV
-2.20%
$2.22
TSLA
-1.07%
$442.60
RF
+1.24%
$24.36
AMZN
+2.56%
$222.03
EOSE
+8.59%
$16.30
GRAB
-1.23%
$5.60
GOOGL
-2.37%
$250.46
AMD
-1.05%
$238.03
AAPL
+0.20%
$262.77
LAES
-5.86%
$6.10
QUBT
-7.40%
$16.00
ACHR
-4.75%
$11.41
IONZ
+1.48%
$4.11
GM
+14.86%
$66.62
SOUN
-4.35%
$18.23
RR
+1.25%
$5.63
BTBT
-8.29%
$3.87
VALE
-1.14%
$11.27
BBD
-2.36%
$3.30
IREN
-6.79%
$55.19
PFE
+0.64%
$24.85
QBTS
-6.42%
$32.19
GPUS
-7.57%
$0.36
DCGO
+24.16%
$1.49
MARA
-3.18%
$20.07
HAL
+11.58%
$25.24
RMBL
+60.50%
$3.21
CJET
-20.45%
$0.08
AAL
+1.47%
$12.35
DFLI
-3.96%
$1.21
ADD
-25.47%
$0.05
CLSK
-7.99%
$18.77
NOK
-2.27%
$5.58
NIO
-3.68%
$6.80
SRM
+53.27%
$10.30
CIFR
-9.21%
$18.07
BMNR
-3.62%
$51.85
AMC
+4.33%
$2.89
KO
+4.06%
$71.22
SNAP
+1.55%
$7.85
PBR
-1.11%
$11.56
ONDS
-7.46%
$7.19
SMR
-13.20%
$38.36
VZ
-1.22%
$40.29
HBAN
+0.63%
$15.94
HIMS
-3.89%
$49.36
CUTR
-10.19%
$0.09
WTO
+2.93%
$0.06
SMCI
-0.39%
$54.82
GGB
-1.17%
$3.37
EPWK
-8.71%
$0.07
WLGS
-5.57%
$0.04
PM
-3.83%
$152.00
RIVN
+0.91%
$13.20
GOOG
-2.20%
$251.34
PLTR
-0.04%
$181.51
BAC
-0.99%
$51.52
APLD
-9.35%
$32.54
RGTZ
+15.11%
$15.61
ETWO
0.00%
$3.30
BULL
-2.96%
$11.14
IONQ
-0.73%
$59.50
MSN
+59.31%
$0.76
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.